UNSPSC 51385703: Tilmacoxib

This classification denotes a cyclooxygenase inhibitor with the molecular formula C16H19FN2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G6VI5P84SX, chemically known as 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo(4,5)imidazo(1,2a)pyridine-4-n-(2-fluorophenyl)carboxamide but generally known as tilmacoxib, which bears US NIH Compound Identifier 159271. The term TILMACOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46).

Most nations schedule tilmacoxib under HS 29350090 and SITC 51580. As of Q4 2014, TILMACOXIB remains the US FDA Preferred Term for this commodity. Tilmacoxib bears US NLM identifiers UMLS ID C2699944 and NCI Concept Code C76640. SMILES: CC1=NC(=C(O1)C2=CC(=C(C=C2)S(=O)(=O)N)F)C3CCCCC3.

UNSPSC 51385703 Tilmacoxib is a Commodity code nominally naming a single nonsteroidal anti-inflammatory drug; however, recent state and local opportunities solicited under this code do not involve tilmacoxib specifically. Instead, Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives with quarterly deliveries, and the Texas Health and Human Services Commission posted an RFI in April 2026 exploring vendor capacity for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP in January 2026 for generic multi-source pharmaceuticals and over-the-counter products distributed through three authorized wholesalers to participating state and local government facilities in Minnesota and Oregon. The mismatch between the code's nominal scope and actual recent solicitations suggests the code carries broad pharmaceutical and health-related products beyond its single-drug name. Issuing bodies include a county health department, a state health and human services commission, and a multistate cooperative purchasing alliance, indicating activity spans local health authorities, state agencies, and regional cooperative vehicles.

Recent activity concentrates in Florida, Texas, and the upper Midwest. Seminole County's naloxone and drug deactivation systems procurement (IFB due July 26, 2023, posted June 30, 2026) required electronic bid submission through the county's e-Procurement Portal with electronic delivery of all bids and shipping costs included in proposals. The Texas HHS Commission's RFI (due April 3, 2026) functions as exploratory market intelligence preceding a formal procurement and does not yet establish binding timelines or award values. MMCAP's generic pharmaceuticals and OTC RFP (due March 26, 2026) targets multistate and local government facilities with a two-year initial term beginning July 1, 2026, and requires NDC-specific product information, compliance with cGMP and the Drug Supply Chain Security Act, and pricing through authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson. The code shows limited recent activity but reflects state and local procurement of pharmaceutical products, health-system supplies, and opioid-response materials through both direct buys and cooperative purchasing frameworks.